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Abstract
Background: Parkinson’s disease (PD) is a neurodegenerative disease with characteristics and symptoms that are
well defined. Nevertheless, its aetiology remains unknown. PD is characterized by the presence of Lewy bodies
inside neurons. α-Synuclein (α-syn) is a soluble protein present in the pre-synaptic terminal of neurons. Evidence
suggests that α-syn has a fundamental role in PD pathogenesis, given that it is an important component of Lewy
bodies localized in the dopaminergic neurons of PD patients.
Methods: In the present study, we investigated the influence of wild type (WT) and A30P α-syn overexpression on
neuroblastoma SH-SY5Y toxicity induced by the conditioned medium (CM) from primary cultures of glia challenged
with lipopolysaccharide (LPS) from Escherichia coli.
Results: We observed that SH-SY5Y cells transduced with α-syn (WT or A30P) and treated with CM from LPS-activated
glia cells show evidence of cell death, which is not reverted by NF-κB inhibition by sodium salicylate or by blockage of
P50 (NF-κB subunit). Furthermore, the expression of A30P α-syn in neuroblastoma SH-SY5Y decreases the cell death
triggered by the CM of activated glia versus WT α-syn or control group. This effect of A30P α-syn may be due to the
low MAPK42/44 phosphorylation. This finding is substantiated by MEK1 inhibition by PD98059, decreasing LDH release
by CM in SH-SY5Y cells.
Conclusion: Our results suggest that SH-SY5Y cells transduced with α-syn (WT or A30P) and treated with CM from LPS-
activated glia cells show cell death, which is not reverted by NF-κB blockage. Additionally, the expression of A30P α-syn
on neuroblastoma SH-SY5Y leads to decreased cell death triggered by the CM of activated glia, when compared to WT
α-syn or control group. The mechanism underlying this process remains to be completely elucidated, but the present
data suggest that MAPK42/44 phosphorylation plays an important role in this process.
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Background
Parkinson’s disease (PD) is the most common neurode-
generative movement disorder [1]. The clinical symp-
toms include rigidity, slowness of movement and
tremor [2, 3]. The pathological hallmark of PD is dopa-
minergic neuronal (DN) loss in the substantia nigra
and the presence of intracellular inclusions called Lewy
bodies, largely composed of aggregated α-synuclein (α-
syn) [4, 5]. The physiological role of α-syn is unknown.
However, recent data supports its role as a synaptic
protein involved in neurotransmitter vesicular release
[6, 7]. Multiplications of the human α-syn gene or point
mutations (A30P, A53K, E46K) are related to familial
autosomal-dominant forms of early-onset PD [8–12].
This suggests that α-syn overexpression or point muta-
tions may accelerate disease onset and progression.
Moreover, genome-wide association studies have identi-
fied SNCA, the gene that encodes α-syn, as having a
strong association with the development of PD [13].
The inflammatory component in PD is reinforced by
studies showing high microglia concentration and in-
creased release of cytokines in the brains of PD patients
[14]. Furthermore, the chronic inflammation in PD that
contributes to DN degeneration is maintained by activated
microglia and astrocytes, as well as T lymphocyte infiltra-
tion from the periphery [15–17]. Activated microglia re-
lease proinflammatory mediators that can amplify the
inflammatory response, producing a deleterious effect in
DN [18–20].
The mechanisms underlying the loss of DN in PD are
still unclear. The nuclear factor-kappa-light-chain-enhan-
cer of activated B cells (NF-κB) is a transcription factor
that regulates gene expression in numerous processes, in-
cluding inflammation and apoptosis [21–23]. NF-κB can
form homodimers or heterodimers from the NF-κB family
of proteins p65 (RelA), p50 (NF-κB1), RelB, cRel and p52
(NF-κB2). The inactive form of NF-κB is kept in the cyto-
sol. Following stimulation, the inhibitor of κB (IκB) pro-
tein is phosphorylated, permitting NF-κB to translocate to
the nucleus. NF-κB is activated in the brains of PD [24]
and Alzheimer’s disease patients [25, 26], contributing
to the pathological progression of these neurodegener-
ative diseases [27]. In this study, we investigated the
NF-κB response in neuroblastoma cells (SH-SY5Y)
overexpressing wild type (WT) or A30P α-syn, which
have been challenged with the conditioned medium
(CM) of lipopolysaccharide (LPS)-stimulated primary
glia cultures. We observed that the treatment of the
WT or A30P α-syn overexpressing cells with CM in-
creased cell death, although the inhibition of NF-κB
did not affect cell death levels. We further demonstrate
that this CM-induced cell death is abrogated by the in-




cDNA coding for WT or A30P human α-syn GenBank no.
NM_000345.2 (kindly provided by Dr. Pamela McLean,
Harvard University, USA) was cloned in the pHRIG lenti-
viral vector (a generous gift from Dr. Robert Sapolsky,
Stanford University, USA). The packaging construct and
vesicular stomatitis virus G protein envelope used were
the pMDL, pREV and pVSVG plasmids (Invitrogen). The
viral particles were produced by transfection of HEK
293 T cells with these plasmids [28].
Primary cell culture
Primary mixed glial cultures were prepared from the
cortex of 1–3-day-old Wistar rats as described [29].
Briefly, cortices free of meninges were digested with
Ca2+- and Mg2+-free HBSS (Invitrogen) containing
0.05 % trypsin and 10 μg/mL DNase (Sigma) and tritu-
rated with DMEM (Invitrogen) containing 10 % heat-
inactivated foetal bovine serum (FBS, Invitrogen) and
1 % penicillin-streptomycin. Dissociated cells were
plated onto 75-cm2 flasks and fed every other day for
14 days. On the 15th day, the cells were treated with
LPS (Escherichia coli 0111:B4, Sigma) 1 μg/mL in
DMEM without FBS for 24 h. The supernatants were
collected and named conditioned medium (CM). All
the experimental procedures were performed in accord-
ance with the standards of the Ethics Committee on
Animal Experimentation of the Institute of Biomedical
Sciences, University of São Paulo (ICB-USP) and followed
all the requirements described in the Brazilian College of
Animal Experimentation (COBEA) in compliance with
the National Institutes of Health guide for the care and
use of laboratory animals. Moreover, all efforts were made
to minimize animal suffering and to reduce the number of
animals used.
Cell culture
SH-SY5Y neuroblastoma cells (CRL-2266, ATCC) were
maintained in DMEM supplemented with 10 % FBS,
100 Units/mL penicillin and 0.1 mg/mL streptomycin in
humidified 5 % CO2 atmosphere at 37 °C. For each experi-
ment, 1 × 105 cells were transduced with 1 × 104 infectious
units per volume of lentivirus containing empty pHRIG,
pHRWT α-synIG or pHRA30 [30]. Experiments were per-
formed in 6-well or 96-well culture plates at 80 % cell con-
fluence. SH-SY5Y cells were treated with CM, PD98059
(Millipore), peptide SN50/SN50M (Calbiochem) or so-
dium salicylate (NaSal, Sigma) for 24 h in DMEM with
0.1 % FBS.
Measurement of TNF-α, IL-1β and KC
The CM of mixed glial culture was collected and con-
centrations of tumour necrosis factor-alpha (TNF-α) and
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interleukin (IL)-1β were measured using commercial
ELISA kits (R&D Systems), following the manufacturer’s
instructions. The detection limit of the method is 10.9
(minimum) and 700 pg/mL (maximum).
Lactate dehydrogenase release assay
As described previously [31], cell viability was evaluated
by lactate dehydrogenase (LDH) release into the cell cul-
ture supernatants by enzymatic test, using the Cytotox
96 kit (Promega). In brief, a volume of 50 μL of culture
medium was transferred to a 96-well microplate, into
which a 50 μL of substrate mix was added and incubated
for 30 min at room temperature, followed by 50 μL of
stop solution (1 M acetic acid). The optical density at
490 nm was measured using a microplate reader
(Biochrom). The percentage of cell death was normal-
ized to the LDH values released after exposing cells for
45 min to lysis solution (9 % Triton X-100), which was
expressed as 100 % cell death.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts from control or treated SH-SY5Y cells
were prepared as previously described [32]. Double-
stranded oligonucleotide containing the NF-κB consen-
sus sequence from Promega (5′-AGTTGAGGGGACTT
TCCCAGGC-3′) was end labelled using T4 polynucleo-
tide kinase (Promega) in the presence of γ-32P dATP.
Nuclear extracts (5 μg) were incubated with 32P-labelled
NF-κB probe. The binding reaction was performed at
room temperature for 30 min in a reaction buffer con-
taining 50 mM Tris-HCl pH 7.5, 250 mM NaCl, 5 mM
MgCl2, 2.5 mM EDTA, 20 % glycerol, 0.25 μg/μL of poly
(dI-dC) and 2.5 mM dithiothreitol. DNA protein com-
plexes were separated by electrophoresis through a 6 %
acrylamide:bis-acrylamide (37.5:1) gel in TBE (45 mM
Tris, 45 mM boric acid, 0.5 mM EDTA) for 2 h at
150 V. Gels were vacuum dried for 1 h at 80 °C and ex-
posed to X-ray film at −80 °C. For competition assays,
5 μg of nuclear extract was incubated with specific com-
petitor (unlabelled double-stranded NF-κB consensus
oligonucleotide) or a non-specific competitor (unlabelled
transcription initiation factor IID [TFIID]). For super-
shift assay, antibodies against subunits of NF-κB (p50,
p65, cRel, RelB 1:20) (Santa Cruz Biotechnology) were
added into the binding reactions.
Western blot analysis
Cells were homogenized in lysis buffer (10 mM HEPES
pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.1 mM EDTA,
30 mM NaF, 3 mM orthovanadate, 0.5 mM DTT, 2 mM
sodium pyrophosphate, 0.5 mM PMSF, 2 μg/mL leupep-
tin, 2 μg/mL antipain) and incubated on ice for 10 min.
After addition of NP-40 (0.5 %), samples were vigorously
mixed and centrifuged for 30 s at 12,000 × g, and the
resulting supernatant was collected. Protein concentra-
tion in cell lysates was determined using a protein assay
kit (Bio-Rad). The immunoblotting was performed as
described previously [26]. The primary antibodies used
were the following: α-synuclein (1:500, BD Transduc-
tion Laboratories), phospho-MAPK42/44 (1:2000, Cell
Signalling Technology), α-tubulin (1:2000, Santa Cruz
Biotechnology) and β-actin (1:2000, Sigma). The HRP-
conjugated secondary antibodies (1:5000, Sigma) were
applied and blots were developed using an ECL kit
(Millipore).
Immunofluorescence
The immunofluorescence was performed as described
previously [26] , with some modifications. Cells were
fixed in cold 4 % formaldehyde for 15 min before incu-
bation in blocking solution (5 % normal donkey serum/
PBS 0.01 % Triton X-100). Cells were incubated with
rabbit anti-GFAP antibody (1:500; Millipore), mouse
anti-MAP2 antibody (1:500; Abcam), mouse anti-CD68
(1:200; Abcam) or anti-TNFR1 (1:300; Abcam) over-
night. After washing in PBS, cells were incubated with
(1:1000) anti-rabbit Alexa Fluor 488 and anti-mouse
Alexa Fluor 594. DAPI was used to stain nuclei. Control
cells were incubated only with secondary antibodies. Im-
ages were analysed under a fluorescence microscope
(Nikon Eclipse 80i) or confocal microscope (Zeiss LSM
780).
Results
Cells treated with CM release LDH in dose-dependent way
After 15 days of culture, the glial cells (Fig. 1a), consist-
ing of astrocytes (GFAP+) and microglia (CD68+) but
free of neurons (MAP2), were challenged with LPS. The
medium was collected and ELISA assay was performed
in order to observe the presence of the cytokines (TNF-
α and IL-1β) and chemokine (KC) (Fig. 1c). To confirm
the presence of TNF-α receptor 1 in all groups, we per-
formed an immunofluorescence (Fig. 1e). In order to
study the role of CM from activated glia treated with
LPS in SH-SY5Y with human α-syn expression, we
observed cell viability. Analysis of the LDH release was
carried out over the 24-h treatment with CM. Based on
the data reported in Fig. 1b, we used 320 μL of CM
(EC50) for 5 × 104 cells in subsequent studies, to observe
the influence of WT and A30P α-syn overexpression on
cell death.
CM-induced cell death is not affected by NaSal treatment
in WT and A30P α-syn
Identification of α-syn overexpression in SH-SY5Y cells
transduced with lentivirus pWT α-synIG (WT α-syn) or
pA30P α-synIG (A30P α-syn) in comparison to cells
transduced with empty vector (pHRIG) is shown in
Yshii et al. Journal of Neuroinflammation  (2015) 12:193 Page 3 of 8
Fig. 1d. As we detected high levels of TNF-α in the CM,
we evaluated the expression of TNFR1 on the cells
transduced with both variants of α-syn, but there was no
difference in TNFR1 levels between the groups (Fig. 1e).
To investigate the role of CM produced by activated glia
on α-syn overexpressing cells, cells were treated with
CM (320 μL/5 × 104 cells) for 24 h. A substantial in-
crease in the percentage of cell death was observed in
pHRIG, WT α-syn and A30P α-syn cells when compared
to non-treated cells (Fig. 2a). However, A30P α-syn cells
treated with CM presented significantly lower LDH re-
lease when compared to pHRIG or WT α-syn cells
treated with CM. To investigate whether the NF-κB sig-
nalling pathway was involved in the cell death caused by
CM, SH-SY5Y cells were treated with NaSal, a NF-κB in-
hibitor. This transcription factor is kept inactive in the
cytoplasm via binding to IκB, which, when phosphory-
lated, releases NF-κB, which then translocates to the nu-
cleus. NaSal inhibits the degradation of IκB, thereby
blocking N-κB activation [33]. The cells were treated
with CM (320 μL/5 × 104 cells) in the presence or ab-
sence of NaSal 10 mM [34] for 24 h. As shown in Fig. 2a,
the CM-mediated cell death was reverted by NaSal treat-
ment only in the control group pHRIG but not in WT
Fig. 1 Characterization of primary glial culture, conditioned medium and overexpression of α-syn. a Immunofluorescence assay was performed in
primary glial culture of rat cortex using (A) GFAP (green), (B) MAP2 (red) or (E) CD68 (red) antibodies. Glial cells are stained with glial-specific glial
fibrillary acidic protein (GFAP) or CD68 (microglia) but not with MAP2. The nuclei are stained with DAPI. Scale bar: 50 μm. b LDH liberation by SH-
SY5Y cells treated with CM. Dose-dependent increase of LDH liberation after treatment with CM on SH-SY5Y cells. The dotted line represents the
cells treated with PBS (19.45 % ± 0.98; n = 6). c Production of inflammatory cytokines or chemokine by activated glia. No detectable quantity of
TNF-α, IL-1β or KC was detected in CM of non-activated glia. The values represent the mean ± SEM of n = 6. d Representative immunoblotting
showing overexpression of α-syn in SH-SY5Y cells. α-Tubulin was used as control. e Empty vector (pHRIG) (A), WT (B) or A30P (C) α-syn-transduced cells
express the same amount of TNFR1 (in red). The nuclei are stained with DAPI
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or A30P α-syn, even though there was significantly less
cell death in A30P α-syn treated with CM when com-
pared to WT α-syn treated with CM.
To investigate the involvement of NF-κB in this
process, we performed an EMSA, observing that the
DNA binding activity to the NF-κB consensus sequence
in cells treated with CM was increased in comparison
with non-treated (NT) cells (Fig. 2b, c). The simultan-
eous incubation of CM and NaSal significantly decreased
this binding activity. The subunits involved in this bind-
ing were p65, cRel and p50 (Fig. 2d), for both WT and
A30P α-syn.
To study whether the p50 subunit of NF-κB partici-
pates in this protection from cell death triggered by CM,
we treated the cells with the inhibitory peptide SN50
(18 μM). As a control, an inactive peptide, SN50M
(18 μM), was used. The control cells, pHRIG, treated
with CM and SN50 showed a significant decrease in cell
death versus cells treated with CM only. No significant
difference was observed on cell death in A30P α-syn
group challenged with CM and treated with or without
SN50. However, there was an increase of LDH release in
WT α-syn cells treated with CM and SN50, when com-
pared with WT α-syn treated with CM alone (Fig. 2e).
Blockage of p42/44 MAPK but not NF-κB abrogates
TNF-α-induced cell death
To determine whether the involvement of TNF-α im-
pacts on the cell death caused by CM, cells were
treated with the TNF-α at 10 ng/mL. As shown in Fig. 3,
TNF-α was capable of causing cell death after 24 h of
incubation. The treatment together with NaSal did not
protect the cells from death. However, the incubation
Fig. 2 Blockage of NF-κB does not rescue cell death caused by CM in WT or A30P a-syn overexpressing cells. a LDH release 24 h after CM treat-
ment. Graph shows mean ± SEM of six independent experiments. The results are expressed as a percentage of maximal LDH release obtained after
complete cell lysis. Two-way ANOVA followed by Bonferroni test: *P < 0.05 vs non-treated cells; #P < 0.05 vs WT α-syn treated with CM or CM +NaSal;
+P < 0.05 vs pHRIG treated with CM. b Densitometry analysis of p65/p50 heterodimers of the nuclear extracts of SH-SY5Y cells. The data represent the
mean ± SEM of five independent experiments. Two-way ANOVA followed with Tukey test: *P < 0.05, **P < 0.01 and ***P < 0.001 in NT, CM + NaSal and
NaSal only treated cells. c Representative EMSA autoradiography. The NF-κB-specific band is indicated by an arrow. NS represents non-specific binding.
d Supershift and competition assay were performed on nuclear extract of SH-SY5Y overexpressing WT α-syn. First lane (from left to right) represents
the WT α-syn treated with CM. Fifth lane represents the presence of unlabelled specific oligonucleotides (NF-κB consensus sequence, fivefold molar
excess). Lane 6 represents the presence of non-specific oligonucleotide (TFIID consensus sequence at fivefold molar excess). Supershift assay was
performed in the absence and presence of antibodies against NF-κB subunits p65, p50 and cRel, as indicated. e Cells treated with CM present with
significant cell death compared to DMSO-treated groups (*P < 0.05 vs DMSO). There is no reduction in cell death (WT and A30P) after treatment with
SN50 concomitantly with CM. Two-way ANOVA followed with Sidak test: #P < 0.05 vs WT α-syn + CM, +P < 0.05 vs WT α-syn + CM. Graph shows mean
± SEM of four to eight independent experiments
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of PD98059 (50 μM), an inhibitor of MEK1 concomi-
tantly with TNF-α, did prevent cell death.
MAPK inhibitor PD98059 protects from CM-induced cell
death
It is suggested that activation of the MAPK pathway can
drive α-syn overexpression [35]. To examine whether
MAPK signalling is protective, cells were treated with
PD98059, a MEK1 inhibitor (50 μM). After pre-treating
the cells with PD98059 for 20 min before the 24-h CM
treatment, we detected a decrease of LDH release when
compared to CM-treated cells without PD98059 (Fig. 4a).
Also, the expression of the phosphorylated form of
MAPK42/44 was assayed by immunoblotting (Fig. 4b).
We could observe that CM treatment significantly in-
creased the expression of pMAPK42/44 in pHRIG cells
but not in WT or A30P α-syn, which was prevented by
PD98059 treatment in pHRIG cells (Fig. 4c).
Discussion
Inflammation is a key process in PD pathogenesis and
disease progression. Activated microglia are present in
PD animal models and patients, as evidenced in sev-
eral studies [36, 37]. Microglia and astrocytes can be-
come reactive during PD, releasing cytokines and
chemokines [38], with reactive astrocytes being harm-
ful to neurons [37]. Astrocytic CM is also toxic to
motor neurons in culture, again increasing cell death
and highlighting the glia role in cell death in different
neuronal subtypes [39, 40].
Here, we demonstrate that CM activated NF-κB. This
can arise as a consequence of the many factors con-
tained in activated glial CM, including several cytokines,
chemokines and growth factors that can trigger NF-κB
nuclear translocation. In the central nervous system,
there is evidence supporting a dual role of NF-κB in
neurodegenerative diseases; activation of neuronal NF-
κB can promote their survival, whereas NF-κB activation
in glial and immune cells mediates pathological inflam-
matory processes [27]. In this report, we show that the
treatment of WT or A30P α-syn cells with CM increases
Fig. 3 Blockage of p42/44 MAPK but not NF-κB abrogates cell death
caused by TNF-α. TNF-α causes significant cell death after 24 h of
incubation (*P < 0.05 vs NT and TNF-α + PD98059), which is abrogated
by PD98059. Treatment with NaSal does not prevent this cell death.
A30P α-syn treated with TNF-α and NaSal shows a higher level of LDH
release (#P < 0.05) vs A30P treated only with TNF-α. Graph shows mean
± SEM of six independent experiments. The results are expressed as a
percentage of maximal LDH release activity obtained after complete
cell lysis
Fig. 4 Blockage of p42/44 MAPK protects the SH-SY5Y cells from death caused by CM. a CM causes significant cell death after 24 h of incubation
(*P < 0.05 vs NT and PD98059), which is decreased by PD98059 (#P < 0.05). Graph shows mean ± SEM of five independent experiments. The results
are expressed as a percentage of maximal LDH release activity obtained after complete cell lysis. b Representative images of phosphorylated and
total form of MAPK42/44 immunoblotting assay. c The densitometric analysis demonstrates that phosphorylation of MAPK42/44 is significantly
higher in pHRIG cells treated with CM versus pHRIG + CM + PD98059. Two-way ANOVA followed with Bonferroni test: *P < 0.05 vs pHRIG + CM
+ PD98059 and A30P α-syn + CM. Graph shows mean ± SEM of four independent experiments
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LDH release when compared to cells with no treatment,
which is not reverted by blockade of IκB degradation by
NaSal or through suppression of the p50 subunit nuclear
translocation, suggesting that CM can trigger cell death
in a NF-κB-independent manner. Indeed, it has been
shown that the interaction between TNF-α and its re-
ceptors activates the signalling complex triggering cell
death via caspase-8 regulation [41, 42]. In this aspect,
we could observe cell death in the presence of TNF-α
in all three groups, and no rescue was observed when
these cells were co-treated with NaSal, reinforcing the
possibility of CM triggering cell death in NF-κB-
independent way.
Moreover, the expression of A30P α-syn on neuro-
blastoma SH-SY5Y decreases cell death triggered by
activated glial CM, when compared to WT α-syn or
control group. This effect of A30P α-syn may be due
to the lower MAPK42/44 phosphorylation when
treated with CM, resulting in reduced cell death in
comparison with WT α-syn. Furthermore, our data
showed that MEK1 inhibition by PD98059 decreases
LDH release by CM in SH-SY5Y cells. Recently,
Lazaro et al. [43] demonstrated that the A30P mutant
showed a reduced propensity to form inclusions when
compared to other familial mutations like E46K,
which could explain our results in which cells overex-
pressing A30P α-syn show less cell death compared
to WT α-syn cells treated with CM.
Convincing evidence shows a protective role for NF-
κB in apoptosis [44]. In fact, we observed that the block-
age of NF-κB activation in the SH-SY5Y cells after
treatment with TNF-α makes the cells more susceptible
to apoptosis, specially in A30P α-syn cells, suggesting
that this mutation is more prone to apoptosis when NF-
κB is blocked. This suggests that the lysosomal dysfunc-
tion [45] could play a role in this process, since LAMP-1
1 (lysosomal-associated membrane protein-1) in A30P
cells is less expressed; therefore this group is more sensi-
tive to exposure to TNF-α, which is known to cause dis-
ruption of lysosomes [46].
Furthermore, when the p50 subunit of NF-κB is inhib-
ited, there is no decrease in LDH release in WT or
A30P α-syn treated with CM, despite the significant re-
duction in the pHRIG group when co-treated with
SN50. Another possibility would be a role for the p65
subunit. The inhibition of p65 activation decreases the
neurodegeneration in mice treated with MPTP [24], sug-
gesting that p65 activation is an important event in this
PD model [47].
Conclusions
In conclusion, our results suggest that SH-SY5Y cells
transduced with α-syn (WT or A30P) and treated with
CM from LPS-activated glia cells show evidence of cell
death, which is not reverted by NF-κB blockage by NaSal
or SN50. Additionally, the expression of A30P α-syn on
neuroblastoma SH-SY5Y leads to decreased cell death
triggered by the CM of activated glia, when compared to
WT α-syn or control group. The mechanism underlying
this process remains to be completely elucidated, but the
present data suggest that the inhibition of MEK1 plays
an important role in this process.
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